Tucotuzumab celmoleukin
Also known as: EMD 273066, huKS-IL2, huKS1/4-IL2, tucotuzumab celmoleukin
Source Tucotuzumab celmoleukin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Tucotuzumab celmoleukin (also known as EMD 273066 or huKS-IL2) is an immunocytokine consisting of a humanized anti-EpCAM IgG1 antibody fused to IL-2. It was investigated in clinical trials for EpCAM-positive solid tumors, particularly ovarian cancer, small-cell lung cancer, and other carcinomas, with the goal of concentrating IL-2 activity at the tumor site to reduce systemic toxicity while enhancing local anti-tumor immunity.
Mechanism of Action
Tucotuzumab celmoleukin is a fusion protein combining an anti-EpCAM humanized monoclonal antibody (tucotuzumab) with interleukin-2 (celmoleukin/IL-2). It targets EpCAM-expressing tumor cells, delivering IL-2 to the tumor microenvironment to stimulate local T-cell and NK-cell proliferation and cytotoxic activity, thereby enhancing anti-tumor immune responses.
Routes of Administration
Goals & Uses
- Ovarian cancer treatmentOncologyModerate
- EpCAM-positive solid tumor treatmentOncologyLow
- Small-cell lung cancer treatmentOncologyLow
- Tumor-targeted IL-2 immunotherapyImmunotherapyModerate
Contraindications
- Severe cardiac diseaseCardiovascularHigh
- Hypersensitivity to IL-2 or anti-EpCAM antibody componentsAllergy/HypersensitivityHigh
- Severe pulmonary dysfunctionPulmonaryHigh
- Active autoimmune diseaseAutoimmunityHigh
Adverse Effects
- Capillary leak syndromeVascularUncommonLeakage of fluid from blood vessels into tissues
- HypotensionCardiovascularUncommonLow blood pressure
- Nausea/vomitingGastrointestinalCommon
- Fever and chillsConstitutionalCommon
- FatigueGeneralCommonLow energy or tiredness
- Infusion-related reactionsHypersensitivityUncommon
Drug Interactions
- CorticosteroidsModerate
- Other immunosuppressantsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
- Patients with organ transplantsImmunologicalRelative
Regulatory Status
- European UnionInvestigationalNo EMA approval; investigated in European clinical trials under development by Merck KGaA.
- United StatesInvestigationalStudied under IND; never approved by FDA. Development largely discontinued.
Never received regulatory approval from FDA, EMA, or other major agencies. Investigated under IND in Phase I/II clinical trials. Development largely discontinued or stalled.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Tucotuzumab celmoleukin?
Tucotuzumab celmoleukin (also known as EMD 273066 or huKS-IL2) is an immunocytokine consisting of a humanized anti-EpCAM IgG1 antibody fused to IL-2. It was investigated in clinical trials for EpCAM-positive solid tumors, particularly ovarian cancer, small-cell lung cancer, and other carcinomas, with the goal of concentrating IL-2 activity at the tumor site to reduce systemic toxicity while enhancing local anti-tumor immunity.
What is Tucotuzumab celmoleukin used for?
Tucotuzumab celmoleukin is educationally associated with: Ovarian cancer treatment, EpCAM-positive solid tumor treatment, Small-cell lung cancer treatment, Tumor-targeted IL-2 immunotherapy. Educational only — not medical advice.
How is Tucotuzumab celmoleukin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Tucotuzumab celmoleukin?
Reported adverse effects include: Capillary leak syndrome, Hypotension, Nausea/vomiting, Fever and chills, Fatigue, Infusion-related reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Tucotuzumab celmoleukin?
Recorded contraindications: Severe cardiac disease, Hypersensitivity to IL-2 or anti-EpCAM antibody components, Severe pulmonary dysfunction, Active autoimmune disease. Consult a qualified clinician before use.